3） Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin—1 antagonist aprepitant for
the prevention of chemotherapy—induced nausea and vomiting：a multinational, random-
ized, double—blind, placebo—controlled trial in patients receiving high—dose cisplatin——the
Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003；21：4112—9.
（Ⅱ）
4） de Wit R, Herrstedt J, Rapoport B, et al. The oral NK（1）antagonist, aprepitant, given with
standard antiemetics provides protection against nausea and vomiting over multiple
cycles of cisplatin—based chemotherapy：a combined analysis of two randomised, pla-
cebo—controlled phase Ⅲ clinical trials. Eur J Cancer. 2004；40：403—10.
（Ⅱ）
5） Barrajon E, de las Peñas R. Randomised double blind crossover study comparing ondan-
setron, granisetron and tropisetron. A cost—benefit analysis. Support Care Cancer. 2000；8：
323—33.
（Ⅱ）
6） del Giglio A, Soares HP, Caparroz C, et al. Granisetron is equivalent to ondansetron for
prophylaxis of chemotherapy—induced nausea and vomiting：results of a meta—analysis of
randomized controlled trials. Cancer. 2000；89：2301—8.
（Ⅰ）
7） Jantunen IT, Muhonen TT, Kataja VV, et al. 5—HT3 receptor antagonists in the prophy-
laxis of acute vomiting induced by moderately emetogenic chemotherapy——a randomised
study. Eur J Cancer. 1993；29A：1669—72.
（Ⅱ）
8） Tsavaris N, Kosmas C, Vadiaka M, et al. Ondansentron and dexamethasone treatment
with different dosing schedules（24 versus 32 mg）in patients with non—small—cell lung
cancer under cisplatin—based chemotherapy：a randomized study. Chemotherapy. 2000；
46：364—70.
（Ⅱ）
9） Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses
of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis
after moderately emetogenic chemotherapy. European Dolasetron Comparative Study
Group. Eur J Cancer. 1996；32A：1523—9.
（Ⅱ）
10） Ettinger DS, Eisenberg PD, Fitts D, et al. A double—blind comparison of the efficacy of two
dose regimens of oral granisetron in preventing acute emesis in patients receiving mod-
erately emetogenic chemotherapy. Cancer. 1996；78：144—51.
（Ⅱ）
11） Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic
efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and
emesis in patients receiving moderately emetogenic chemotherapy：a phase Ⅲ trial by
the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994；12：
1050—7.
（Ⅱ）
12） Aapro MS, Grunberg SM, Manikhas GM, et al. A phase Ⅲ, double—blind, randomized trial
of palonosetron compared with ondansetron in preventing chemotherapy—induced nau-
sea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006；17：1441—
9.
（Ⅱ）
13） Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus
dexamethasone for prevention of nausea and vomiting during chemotherapy：a double—
blind, double—dummy, randomised, comparative phase Ⅲ trial. Lancet Oncol. 2009；10：
115—24.
（Ⅱ）
14） Grunberg S, Chua D, Maru A, et al. Single—dose fosaprepitant for the prevention of che-
motherapy—induced nausea and vomiting associated with cisplatin therapy：randomized,
double—blind study protocol——EASE. J Clin Oncol. 2011；29：1495—501.
（Ⅰ）
15） Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemo-
therapy—induced nausea and vomiting：a randomized phase Ⅲ trial. J Support Oncol.
2011；9：188—95.
（Ⅱ）
16） Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepi-
tant／fosaprepitant in patients with colorectal cancer receiving oxaliplatin—based chemo-
therapy（SENRI trial）：A multicentre, randomised, controlled phase 3 trial. Eur J Cancer.
2015；51：1274—82.
（Ⅱ）
39
CQ2